Which may also be expressed as an expectation for a particular quality at a particular cost. There are no deadweights to exploit in insulin production. It seems to some people that regulation is the deadweight but without that quality guarantee you’re dependent on suppliers which duplicates the cost of “self regulation” across the sector.
Also that. But overregulation makes too hard for others to compete and offer cheaper insulin.